| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00013-2596-20 | 00013-2596 | Idarubicin Hydrochloride | Idamycin PFS | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 11, 2024 | In Use | |
| 50242-0079-08 | 50242-0079 | Inavolisib | Itovebi | 9.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Oral | Oct 14, 2024 | In Use | |
| 00781-3139-80 | 00781-3139 | Decitabine | Decitabine | 50.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug 28, 2014 | May 31, 2019 | No Longer Used |
| 50268-0761-12 | 50268-0761 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 23, 2017 | In Use | |
| 68001-0564-22 | 68001-0564 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Apr 10, 2023 | In Use | |
| 60505-6271-01 | 60505-6271 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 23, 2024 | In Use | |
| 62332-0813-50 | 62332-0813 | Nelarabine | NELARABINE | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 1, 2024 | In Use | |
| 69097-0516-07 | 69097-0516 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jan 18, 2019 | In Use | |
| 45963-0614-85 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug 10, 2018 | Jun 30, 2023 | In Use |
| 00013-1116-83 | 00013-1116 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec 23, 1987 | Jan 1, 2011 | No Longer Used | |
| 50419-0171-00 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 68727-0745-01 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug 3, 2017 | In Use | |
| 71288-0172-21 | 71288-0172 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 11, 2024 | In Use | |
| 47335-0891-21 | 47335-0891 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 70255-0010-03 | 70255-0010 | BINIMETINIB | MEKTOVI | 15.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | Jun 27, 2018 | In Use | |
| 00019-9450-02 | 00019-9450 | Sodium Iodide I-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Aug 22, 2011 | Jul 1, 2017 | No Longer Used |
| 00085-1417-01 | 00085-1417 | Temozolomide | Temodar | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | Oct 22, 2014 | In Use |
| 31722-0362-31 | 31722-0362 | MELPHALAN HYDROCHLORIDE | MELPHALAN HYDROCHLORIDE | 50.0 mg/10ml | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | May 23, 2024 | In Use | |
| 82804-0136-30 | 82804-0136 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug 28, 2024 | In Use | |
| 47335-0082-50 | 47335-0082 | Doxorubicin Hydrochloride | LIPODOX | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb 9, 2012 | May 29, 2015 | In Use |
| 66758-0050-03 | 66758-0050 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jun 29, 2011 | In Use | |
| 13668-0682-74 | 13668-0682 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 12, 2023 | In Use | |
| 50881-0015-60 | 50881-0015 | Ruxolitinib | Jakafi | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Nov 16, 2011 | In Use | |
| 16729-0391-30 | 16729-0391 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 24, 2018 | In Use | |
| 25021-0261-50 | 25021-0261 | Pemetrexed Disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec 15, 2024 | In Use |
Found 12159 results — Export these results
Home